Lilly Lifts 2026 Revenue Outlook To $91 Billion-$92 Billion, But $4.57 A Share In Deal Charges Cuts Profit Forecast

Third-quarter revenue rose 39% on Mounjaro and Zepbound, yet acquired research charges pulled the full-year earnings range lower.

Share
Lilly Lifts 2026 Revenue Outlook To $91 Billion-$92 Billion, But $4.57 A Share In Deal Charges Cuts Profit Forecast

Eli Lilly, the drugmaker behind Mounjaro and Zepbound, said Thursday that third-quarter revenue rose 39% to $24.4 billion and raised its 2026 sales forecast, while $4.57 a share of acquired research charges lowered its full-year earnings guidance.

Volume up 53%, prices down 15%

Third-quarter growth came from a 53% increase in volume, partly offset by a 15% drop in realized prices, the company reported in an 8-K and attached press release. Worldwide Mounjaro revenue climbed 65% to $10.7 billion, and U.S. Zepbound revenue rose 48% to $5.3 billion.

U.S. revenue increased 34% to $15.1 billion, while revenue outside the U.S. rose 47% to $9.3 billion. Lower prices abroad were driven mainly by Mounjaro's addition to China's National Reimbursement Drug List.

The quarter included about $900 million of benefits, primarily $410 million of Jardiance milestone payments, which Lilly said have no further milestones remaining, plus favorable adjustments to rebate and discount estimates.

Guidance: sales up, earnings down

Lilly now expects 2026 revenue of $91 billion to $92 billion, up from $85 billion to $87 billion, a $5.5 billion increase at the midpoint. Earnings per share guidance moved to $35.00 to $36.00 from $35.50 to $36.50.

The company raised underlying adjusted earnings guidance by $4.07 at the midpoint, but $4.57 of acquired in-process research and development charges from third-quarter deals more than offset it. Those charges primarily related to the acquisitions of AtaiBeckley and Curevo, and totaled $4.2 billion, against $656 million a year earlier.

Reported earnings per share rose 16% to $7.22. The adjusted figure rose 7% to $7.48. Both carried the $4.57 charge, compared with $0.71 in the year-earlier quarter.

Margins, pipeline and next steps

Eli Lilly discovers, develops and sells medicines for diabetes, obesity, cancer, immune and neurological conditions. Gross margin as a percent of revenue was 83.9%, up 1.0 percentage points. Research and development spending rose 23% to $4.2 billion.

Chair and CEO David A. Ricks credited "broad global consumer demand for Mounjaro and Zepbound," and said revenue also reflected global launches of Foundayo. Lilly also completed the Merida Biosciences acquisition after quarter end.

The company reported positive topline results from a head-to-head late-stage trial of retatrutide against Ozempic 2 mg in type 2 diabetes. Late-stage trials of EloraTZP are slated to start in the fourth quarter.

Lilly's earnings conference call began at 10 a.m. Eastern on Thursday.

Sources